Arrowhead Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARWR) $24.93 +1.76 (+7.60%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$23.20▼$24.9350-Day Range$21.20▼$29.1252-Week Range$20.67▼$42.48Volume2.80 million shsAverage Volume1.05 million shsMarket Capitalization$2.68 billionP/E RatioN/ADividend YieldN/APrice Target$53.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Arrowhead Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside105.2% Upside$51.15 Price TargetShort InterestBearish7.80% of Float Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.47Based on 24 Articles This WeekInsider TradingSelling Shares$2.82 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.72) to ($2.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector492nd out of 952 stocksPharmaceutical Preparations Industry232nd out of 434 stocks 3.3 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.15, Arrowhead Pharmaceuticals has a forecasted upside of 105.2% from its current price of $24.93.Amount of Analyst CoverageArrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.80% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 9.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.55. Previous Next 3.0 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Arrowhead Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest3 people have searched for ARWR on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,821,465.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions65.98% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($2.72) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -12.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -12.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 9.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.Read More ARWR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARWR Stock News HeadlinesDecember 4, 2023 | msn.comB of A Securities Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Buy RecommendationDecember 4, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Arrowhead PharmaDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 4, 2023 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expected to Earn Q1 2024 Earnings of ($0.33) Per ShareDecember 2, 2023 | markets.businessinsider.comArrowhead Pharmaceuticals Earns ‘Buy’ Rating on Strong Clinical Pipeline and Strategic Growth PotentialDecember 2, 2023 | americanbankingnews.comRoyal Bank of Canada Reiterates Outperform Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)December 2, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) PT Lowered to $37.00 at Morgan StanleyDecember 2, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low After Analyst DowngradeDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 1, 2023 | markets.businessinsider.comArrowhead Pharmaceuticals: Balancing Pipeline Progress and Financial RisksDecember 1, 2023 | seekingalpha.comArrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be AddressedDecember 1, 2023 | americanbankingnews.comCritical Review: Arrowhead Pharmaceuticals (NASDAQ:ARWR) & Evolus (NASDAQ:EOLS)December 1, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down Following Analyst DowngradeDecember 1, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Guardion Health Sciences (GHSI)November 30, 2023 | finance.yahoo.comQ4 2023 Arrowhead Pharmaceuticals Inc Earnings CallNovember 30, 2023 | markets.businessinsider.comArrowhead Pharmaceuticals Receives Buy Rating on Strong Pipeline and Upcoming CatalystsNovember 29, 2023 | markets.businessinsider.comHold Rating on Arrowhead Pharmaceuticals Awaiting ARO-DM1 Clinical Trial ResultsNovember 28, 2023 | stocknews.com3 Pharma Stocks on the Rise - It's Time to Buy NowNovember 28, 2023 | finance.yahoo.comArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic DystrophyNovember 21, 2023 | finance.yahoo.comArrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare ConferenceNovember 15, 2023 | markets.businessinsider.comCiti Reaffirms Their Hold Rating on Arrowhead Pharmaceuticals (ARWR)November 6, 2023 | finance.yahoo.comArrowhead Pharmaceuticals to Participate in Jefferies London Healthcare ConferenceNovember 3, 2023 | markets.businessinsider.comArrowhead Pharmaceuticals’ Hold Rating: Impact of GSK Collaboration and Future Prospects for JNJ-3989November 2, 2023 | finance.yahoo.comArrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023October 31, 2023 | reuters.comGSK to pay $1 bln for exclusive license to J&J's hepatitis B therapyOctober 31, 2023 | msn.comJohnson & Johnson Offloads Rights For Hepatitis B Candidate To GSKOctober 26, 2023 | seekingalpha.comArrowhead Pharmaceuticals: A High-Risk, High-Reward BetSee More Headlines Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2023Today12/04/2023Next Earnings (Estimated)2/05/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees397Year FoundedN/APrice Target and Rating Average Stock Price Target$51.15 High Stock Price Target$90.00 Low Stock Price Target$27.00 Potential Upside/Downside+112.6%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,270,000.00 Net Margins-85.27% Pretax Margin-85.78% Return on Equity-53.65% Return on Assets-24.55% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio3.98 Sales & Book Value Annual Sales$240.74 million Price / Sales11.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book9.30Miscellaneous Outstanding Shares107,430,000Free Float102,060,000Market Cap$2.68 billion OptionableOptionable Beta0.78 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Christopher R. Anzalone Ph.D. (Age 54)CEO, President & Director Comp: $1.65MMr. Kenneth A. Myszkowski (Age 57)Chief Financial Officer Comp: $761.55kMr. Patrick O'Brien J.D. (Age 59)PharmD, COO, General Counsel & Secretary Comp: $749.86kDr. James C. Hamilton M.D. (Age 45)MBA, Chief of Discovery & Translational Medicine Comp: $676.81kMs. Tracie OliverChief Commercial OfficerDr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoDr. Vincent Anzalone CFAHead of Investor Relations & VPMr. Howard LovyDirector of CommunicationsDr. Mark Seefeld (Age 69)Head of Toxicology & VP Dr. Javier San Martin M.D. (Age 58)Chief Medical Officer Comp: $658.48kMore ExecutivesKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMCytokineticsNASDAQ:CYTKUltragenyx PharmaceuticalNASDAQ:RAREOrganon & Co.NYSE:OGNPrestige Consumer HealthcareNYSE:PBHView All CompetitorsInsiders & InstitutionsBanque Pictet & Cie SASold 6,229 shares on 11/27/2023Ownership: 0.123%Deutsche Bank AGBought 5,446 shares on 11/24/2023Ownership: 0.208%EP Wealth Advisors LLCBought 7,607 shares on 11/24/2023Ownership: 0.008%Walleye Trading LLCSold 4,300 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCSold 4,600 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ARWR Stock Analysis - Frequently Asked Questions Should I buy or sell Arrowhead Pharmaceuticals stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares. View ARWR analyst ratings or view top-rated stocks. What is Arrowhead Pharmaceuticals' stock price target for 2024? 15 equities research analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' shares. Their ARWR share price targets range from $27.00 to $90.00. On average, they anticipate the company's share price to reach $51.15 in the next year. This suggests a possible upside of 105.2% from the stock's current price. View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts. How have ARWR shares performed in 2023? Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of 2023. Since then, ARWR shares have decreased by 38.5% and is now trading at $24.93. View the best growth stocks for 2023 here. Are investors shorting Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 7,880,000 shares, an increase of 9.9% from the October 31st total of 7,170,000 shares. Based on an average daily trading volume, of 995,100 shares, the short-interest ratio is presently 7.9 days. Approximately 7.8% of the company's stock are short sold. View Arrowhead Pharmaceuticals' Short Interest. When is Arrowhead Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024. View our ARWR earnings forecast. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.38. The biotechnology company had revenue of $15.83 million for the quarter, compared to analyst estimates of $45.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 85.27%. Arrowhead Pharmaceuticals's revenue was down 51.2% on a year-over-year basis. During the same period last year, the firm earned ($0.68) earnings per share. What ETFs hold Arrowhead Pharmaceuticals' stock? ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), Neuberger Berman Disrupters ETF (NBDS), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and AI Powered Equity ETF (AIEQ). What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD). Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (4.02%), JPMorgan Chase & Co. (2.60%), Invesco Ltd. (2.28%), Northern Trust Corp (1.18%), Avidity Partners Management LP (0.99%) and Bank of New York Mellon Corp (0.92%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ARWR) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.